The global Afinitor drug market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market is the increase in the number of organ transplants and rising incidences of chronic diseases such as cancer. According to the US Health Resources and Services Administration, in 2020, nearly 39,000 organ transplants were performed in the US. With the increasing prevalence of chronic diseases such as kidney disease and liver disease, there is high demand for organ transplantation. Every 9 minutes, a new person is added to the transplant waiting list. Therefore, the demand for the Afinitor drugs is growing significantly which is an immunosuppressant used after the organ transplantation procedure is performed.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/afinitor-drug-market
The Afinitor drug is also used for the treatment of cancer. The active substance present is known as everolimus that blocks the mammalian target of rapamycin mTOR. It forms a complex with the FKBP-12 protein which in turn, blocks the mTOR. mTOR is present inside the cell and supports cell division by blocking off the mTOR and the cancer spread slows down. This drug is used in the treatment of various cancers which include breast cancer, pancreatic neuroendocrine tumours, renal cell carcinoma, and many others. Afinitor was launched by Novartis in 2009, after the approval of the US FDA. In 2019, Novartis reported nearly $1 billion in sales of Afinitor. Many generic drugs maker have started making the generics for the drugs as the patent has expired. In December 2019, the US FDA approved the first two generics of Novartis’ cancer drug Afinitor (everolimus) by Par Pharmaceuticals and Teva Pharmaceutical Industries Ltd. Both companies gained approval for everolimus tablets in 2.5 mg, 5, mg, and 7mg doses. Teva also picked up an additional approval for the drug in a 10 mg dose.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Afinitor Drug Market
By Type
- 5 mg
- 5 mg
- 7 mg
- 10 mg
By Application
- Hospitals
- Drug Stores
- Others
A full report of Afinitor Drug Market is available at: https://www.omrglobal.com/industry-reports/afinitor-drug-market
Afinitor Drug Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Novartis International AG
- Teva Pharmaceuticals Industries Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
Visit more report at
https://www.linkedin.com/pulse/scaffold-technology-market-size-trends-latest-arti-vishwakarma-mlsof/